Activity 4I. Drug Interactions with Glecaprevir-Pibrentasvir PDF Share Learning Objective Performance Indicators Provide a rationale for treating all people with HCV except persons with less than a 12-month life expectancy Adhere to inclusion and exclusion criteria for who is eligible to receive simplified HCV treatment Choose an appropriate recommended regimen for simplified HCV treatment Conduct laboratory monitoring for persons receiving simplified HCV treatment, including assessment for sustained virologic response Manage incomplete treatment adherence based on time into treatment and number of days of missed doses Activity QuestionYou should answer this question after completing the activity. You must answer all of the questions before checking your work. This activity has a Check on Learning question. - Show Question Which one of the following patients can you initiate HCV treatment with glecaprevir-pibrentasvir and without the need to change any of their current modifications? A 37-year-old woman who is currently taking ethinyl estradiol A 63-year-old man with ischemic heart disease who is currently taking atorvastatin A 22-year-old man who is taking the anticonvulsant carbamazepine A 32-year-old man with HIV who is currently taking dolutegravir and tenofovir alafenamide-emtricitabine. Share by e-mail From:Enter your e-mail address To: Enter the e-mail address of the recipient Your Message: Check-On-LearningQuestionsThe Check-on-Learning Questions are short and topic related. They are meant to help you stay on track throughout each lesson and check your understanding of key concepts.You must be signed in to customize your interaction with these questions.
